Intertek shares surge as board signals readiness to back £10.6bn EQT takeover bid

Intertek Group shares rose 7.3% to 5,687p after the board said it would be minded to recommend EQT's £60-a-share offer, valuing the company at £10.6 billion. The bid is EQT's fourth and final approach, following earlier rejected offers of £51.50, £54.00 and £58.00 per share. The move signals a materially improved takeover outcome and is likely to support the stock near the offer price.

Analysis

This looks less like a simple bid-up and more like a valuation reset for the broader UK services / testing complex. A takeout at the high end effectively validates premium multiples for regulated, mission-critical assurance assets, which should tighten spreads across listed peers and make consolidation a more viable path for strategics and sponsor-backed buyers. The second-order effect is that standalone operators with durable certification franchises may now trade on M&A optionality rather than near-term organic growth.

The main near-term winner is the bidder’s peer set, not just the target: if a global industrial buyer is willing to stretch for a quality compounder, adjacent companies with similar recurring revenue and sticky client relationships should re-rate on scarcity value. The loser is any short-duration holder betting on mean reversion in premium UK small/mid-cap valuation gaps; this kind of deal can force passive and event-driven flows into a broader basket of “quality” names over the next several weeks. For the acquirer, the risk is disciplined capital allocation: repeated upgrades in offer price signal a potential winner’s-curse dynamic and could pressure the stock if investors start discounting synergy credibility or overpayment.

The key catalyst window is days to weeks, not months: confirmation, board language, and any activist/arbitrage positioning will determine whether the premium compresses into a firm deal or leaks higher on deal certainty. Tail risk is regulatory or financing friction, but the larger risk is simply that the market has already moved most of the obvious upside; the asymmetry now shifts from target alpha to spread capture and relative value. Contrarian take: the headline premium may be too quickly extrapolated into a sector-wide M&A wave, when in reality only a narrow subset of assets with sticky revenues and low cyclicality deserve this multiple.

For the bidder, any extended pursuit raises the probability of negative share reaction if synergies do not clearly exceed the premium paid; that makes the acquirer a tactical short on pullbacks if the market starts to price in overbidding rather than strategic accretion. For the target ecosystem, the best-risk trade is to own the most comparable listed peer basket into the next 2-6 weeks, while fading names that screened as cheap only because they lacked takeover appeal.

Key Decisions for Investors

• Go long the most comparable listed UK testing/inspection peer basket for 2-6 weeks; this is a relative-value trade on M&A multiple spillover, not just target-specific upside.
• Avoid chasing the target after the initial gap; if the stock trades to a premium that implies deal certainty, the remaining upside is likely spread-capture, not fundamental rerating.
• Consider a tactical short in the bidder on strength if the market begins to price winner’s-curse risk or if the offer incrementally moves higher without visible synergy disclosure.
• Pair trade: long quality assurance / services peers, short a broad UK cyclicals basket for 1-2 months; the catalyst is re-rating of defensive, recurring-revenue assets versus economically sensitive names.
• If no formal acceptance arrives within 1-2 weeks, trim risk aggressively; event-driven upside decays quickly once the market has priced the fourth-and-final approach narrative.